BR112022021370A2 - Composto, e, método de tratamento de uma doença ou distúrbio - Google Patents
Composto, e, método de tratamento de uma doença ou distúrbioInfo
- Publication number
- BR112022021370A2 BR112022021370A2 BR112022021370A BR112022021370A BR112022021370A2 BR 112022021370 A2 BR112022021370 A2 BR 112022021370A2 BR 112022021370 A BR112022021370 A BR 112022021370A BR 112022021370 A BR112022021370 A BR 112022021370A BR 112022021370 A2 BR112022021370 A2 BR 112022021370A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- disorder
- disease
- compound
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
COMPOSTO, E, MÉTODO DE TRATAMENTO DE UMA DOENÇA OU DISTÚRBIO. A presente invenção refere-se a compostos que são ativadores de Nrf2. Os compostos têm a fórmula estrutural I definida no presente documento. A presente invenção também se refere a processos para a preparação desses compostos, a composições farmacêuticas que compreendem os mesmos e ao seu uso no tratamento de doenças ou distúrbios associados à ativação de Nrf2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2005852.5A GB202005852D0 (en) | 2020-04-22 | 2020-04-22 | Therapeutic compounds |
PCT/GB2021/050975 WO2021214472A1 (en) | 2020-04-22 | 2021-04-22 | Tetrahydroisoquinoline compounds as nrf2 activators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022021370A2 true BR112022021370A2 (pt) | 2022-12-06 |
Family
ID=70859963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022021370A BR112022021370A2 (pt) | 2020-04-22 | 2021-04-22 | Composto, e, método de tratamento de uma doença ou distúrbio |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230159511A1 (pt) |
EP (1) | EP4139295A1 (pt) |
JP (1) | JP2023524207A (pt) |
KR (1) | KR20230004722A (pt) |
CN (1) | CN115667242A (pt) |
AR (1) | AR121913A1 (pt) |
AU (1) | AU2021258539A1 (pt) |
BR (1) | BR112022021370A2 (pt) |
CA (1) | CA3174360A1 (pt) |
GB (1) | GB202005852D0 (pt) |
IL (1) | IL297440A (pt) |
MX (1) | MX2022013396A (pt) |
WO (1) | WO2021214472A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202325286A (zh) | 2021-10-25 | 2023-07-01 | 英商C4X探索有限公司 | 治療性雙官能化合物 |
WO2024130411A1 (en) * | 2022-12-21 | 2024-06-27 | Variational Ai Inc. | Protease inhibitors and methods of using same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013067036A1 (en) * | 2011-10-31 | 2013-05-10 | Rutgers, The State University Of New Jersey | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
EP3307719A1 (en) * | 2015-06-15 | 2018-04-18 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
CA3114859A1 (en) | 2018-10-22 | 2020-04-30 | C4X Discovery Limited | Therapeutic compounds |
-
2020
- 2020-04-22 GB GBGB2005852.5A patent/GB202005852D0/en not_active Ceased
-
2021
- 2021-04-22 AU AU2021258539A patent/AU2021258539A1/en active Pending
- 2021-04-22 JP JP2022564532A patent/JP2023524207A/ja active Pending
- 2021-04-22 AR ARP210101081A patent/AR121913A1/es unknown
- 2021-04-22 US US17/920,244 patent/US20230159511A1/en active Pending
- 2021-04-22 CN CN202180030434.4A patent/CN115667242A/zh active Pending
- 2021-04-22 IL IL297440A patent/IL297440A/en unknown
- 2021-04-22 CA CA3174360A patent/CA3174360A1/en active Pending
- 2021-04-22 MX MX2022013396A patent/MX2022013396A/es unknown
- 2021-04-22 KR KR1020227040564A patent/KR20230004722A/ko active Search and Examination
- 2021-04-22 BR BR112022021370A patent/BR112022021370A2/pt unknown
- 2021-04-22 WO PCT/GB2021/050975 patent/WO2021214472A1/en active Application Filing
- 2021-04-22 EP EP21724005.0A patent/EP4139295A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
GB202005852D0 (en) | 2020-06-03 |
AR121913A1 (es) | 2022-07-20 |
CN115667242A (zh) | 2023-01-31 |
EP4139295A1 (en) | 2023-03-01 |
WO2021214472A1 (en) | 2021-10-28 |
KR20230004722A (ko) | 2023-01-06 |
JP2023524207A (ja) | 2023-06-09 |
CA3174360A1 (en) | 2021-10-28 |
AU2021258539A1 (en) | 2022-11-10 |
MX2022013396A (es) | 2022-12-13 |
IL297440A (en) | 2022-12-01 |
US20230159511A1 (en) | 2023-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
BR112019007039A2 (pt) | pirrolidinas substituídas e seus métodos de uso no tratamento de fibrose cística | |
BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
BR112022021370A2 (pt) | Composto, e, método de tratamento de uma doença ou distúrbio | |
BR112017023740A2 (pt) | ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida? | |
BR112021025928A2 (pt) | Métodos de preparação de ácido bempedoico e composições do mesmo | |
BR112022018600A2 (pt) | Compostos, composição farmacêutica, método de tratamento de uma doença e combinação | |
BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
BR112022023271A2 (pt) | Compostos | |
BR112022024045A2 (pt) | Moduladores il-17a | |
BR112017018643A2 (pt) | "derivados de tetra-hidrotiazepina bicíclicos úteis, composição farmacêutica compreendendo os mesmos, seu uso, e método in vitro ou ex vivo para a produção de células imunes ativadas" | |
BR112018072755A2 (pt) | composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica | |
BR112023001957A2 (pt) | Composições e métodos para inibir expressão de lpa | |
BR112022023983A2 (pt) | Compostos terapêuticos | |
PH12021550872A1 (en) | Therapeutic compounds | |
BR112021021477A2 (pt) | Composto, composição farmacêutica e método para tratar uma doença mediada por jak em um indivíduo necessitando do mesmo | |
BR112022020798A2 (pt) | Compostos tricíclicos como inibidores de nlrp3 | |
BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
BR112021024325A2 (pt) | Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
BR112017022757A2 (pt) | derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap) | |
BR112023001861A2 (pt) | Composições e métodos para tratamento de doenças e distúrbios | |
BR112022025005A2 (pt) | Formação de imagem e terapia dirigidas por granzima b | |
BR112019023109A2 (pt) | Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo |